×
About 873 results

ALLMedicine™ Mucosal Melanoma Center

Research & Reviews  307 results

Mucosal Melanoma of the Oral Cavity: What is the Role of Elective Neck Dissection?
https://doi.org/10.1002/lary.30152
The Laryngoscope; Haimowitz S, Cohen DA et. al.

May 14th, 2022 - Mucosal melanoma (MM) is a rare malignancy that can present in the head and neck (H&N). The Oral cavity is the second most common primary site in the H&N after sinonasal mucosa. This study investigates the impact of demographic and clinical factor...

Melanoma in Skin of Color: Part I. Epidemiology and clinical presentation.
https://doi.org/10.1016/j.jaad.2022.04.056
Journal of the American Academy of Dermatology; Brunsgaard E, Wu YP et. al.

May 10th, 2022 - Although there is a higher incidence of melanoma among non-Hispanic white individuals, melanoma is diagnosed at more advanced stages and associated with worse survival rates among individuals with skin of color (SOC). The proportion of melanoma su...

Evolving Treatment Approaches to Mucosal Melanoma.
https://doi.org/10.1007/s11912-022-01225-z 10.1038/nrc.2016.37 10.6004/jnccn.2012.0034 10.1200/JCO.2011.36.8829 10.1093/annonc/mdw694 10.1016/j.jaad.2018.09.054 10.1200/JCO.2021.39.15_suppl.e21520 10.1001/archdermatol.2011.264 10.1016/j.jaad.2016.08.007 10.1016/j.jaad.2020.08.097 10.1186/1471-2407-11-85 10.1111/ajco.12802 10.1002/path.4204 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G 10.1016/j.ejca.2017.05.014 10.1245/s10434-018-6503-9 10.1002/path.5017 10.1016/j.cell.2012.06.024 10.1038/nature22071 10.1016/j.semcancer.2019.09.013 10.1111/pcmr.12865 10.1038/nature11071 10.1016/j.cell.2015.05.044 10.1158/1078-0432.CCR-17-0980 10.1016/j.ejca.2017.11.011 10.1016/j.ejca.2016.06.019 10.1038/s41467-020-20432-5 10.1186/s12967-019-1987-z 10.1038/ng.3361 10.1200/JCO.2005.01.5180 10.1200/JCO.2018.36.15_suppl.e21530 10.1158/1078-0432.CCR-19-3922 10.1200/JCO.2016.67.9258 10.1517/14712598.7.4.449 10.1084/jem.20140559 10.1182/blood.V92.11.4150 10.1038/nm1096-1096 10.1007/s00262-013-1500-0 10.1111/cei.12069 10.1200/JCO.20.00902 10.1016/j.ejca.2004.04.030 10.1158/1078-0432.CCR-13-0739 10.1200/JCO.19.00210 10.2217/mmt-2018-0003 10.1200/JCO.2019.37.15_suppl.e21060 10.1016/S1470-2045(08)70254-7 10.1002/hed.20901 10.1186/s12885-015-1750-7 10.1007/s00432-016-2245-x 10.1056/NEJMoa1709030 10.1016/S1470-2045(20)30494-0 10.1200/JCO.2021.39.15_suppl.e18042 10.1093/annonc/mdx339 10.1016/S1470-2045(14)70012-9 10.1056/NEJMoa1904059 10.1016/S1470-2045(18)30497-2 10.1016/j.ejca.2019.11.016 10.1016/S0092-8674(04)00215-6 10.1200/JCO.2017.35.15_suppl.e21017 10.1038/onc.2016.486 10.1016/S1470-2045(13)70024-X 10.1016/S1470-2045(17)30180-8 10.1158/1078-0432.CCR-10-2346 10.1038/modpathol.2016.179 10.1136/jclinpath-2014-202572 10.1200/JCO.2010.33.9275 10.1093/annonc/mdx079 10.1016/j.annonc.2021.08.1467 10.1016/j.ejca.2013.09.007 10.1155/2018/1908065 10.1007/s00262-019-02351-7 10.1038/s41416-018-0207-6 10.1016/j.tranon.2019.02.007 10.1080/2162402X.2020.1736792 10.1200/JCO.19.01598 10.1158/2159-8290.CD-19-1510 10.1158/1078-0432.CCR-21-0251 10.1200/JCO.2020.38.15_suppl.e22043
Current Oncology Reports; Zhang S, Zhang J et. al.

May 6th, 2022 - This review mainly focuses on the unique features and the development of available therapeutic options for mucosal melanoma in different treatment settings, i.e., neoadjuvant, adjuvant, and palliative. Mucosal melanoma is distinct from cutaneous m...

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
https://clinicaltrials.gov/ct2/show/NCT04830124

May 4th, 2022 - This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
https://clinicaltrials.gov/ct2/show/NCT05111574

Apr 22nd, 2022 - PRIMARY OBJECTIVE: I. To compare the efficacy of adjuvant nivolumab (480 mg every [q]4 weeks) versus nivolumab plus cabozantinib s-malate (cabozantinib) (40 mg daily) in patients with mucosal melanoma. SECONDARY OBJECTIVES: I. To compare overall s...

see more →

Guidelines  2 results

Clinical features, molecular characteristics and surgical management of primary penile ...
https://doi.org/10.1097/CMR.0000000000000788
Melanoma Research; Cakir OO, Pozzi E et. al.

Nov 30th, 2021 - Penile mucosal melanoma is an aggressive and rare genital malignancy. The aim of the present study was to review the management and outcomes of a homogenous cohort of patients with histologically confirmed penile mucosal melanoma, at a single spec...

Mucosal melanoma of the head and neck.
https://doi.org/10.6004/jnccn.2012.0033
Journal of the National Comprehensive Cancer Network : JN... Pfister DG, Ang KK et. al.

Mar 7th, 2012 - Mucosal melanoma of the head and neck.|2012|Pfister DG,Ang KK,Brizel DM,Burtness B,Cmelak AJ,|diagnosis,therapy,diagnosis,therapy,pathology,

see more →

Clinicaltrials.gov  9 results

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
https://clinicaltrials.gov/ct2/show/NCT04830124

May 4th, 2022 - This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
https://clinicaltrials.gov/ct2/show/NCT05111574

Apr 22nd, 2022 - PRIMARY OBJECTIVE: I. To compare the efficacy of adjuvant nivolumab (480 mg every [q]4 weeks) versus nivolumab plus cabozantinib s-malate (cabozantinib) (40 mg daily) in patients with mucosal melanoma. SECONDARY OBJECTIVES: I. To compare overall s...

Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
https://clinicaltrials.gov/ct2/show/NCT04180995

Jan 31st, 2022 - This study is one monocentric, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab monoclonal injection (Tuo Yi) combined with axitinib tablet (Inlyta®) as neoadjuvant therapy for localized mucosal melanoma....

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
https://clinicaltrials.gov/ct2/show/NCT04979585

Aug 3rd, 2021 - The current traditional cytotoxic single agent or combination chemotherapy cannot clearly improve the overall survival rate of patients with advanced melanoma.From the current point of view, combination therapy will be one of the inevitable trends...

Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma
https://clinicaltrials.gov/ct2/show/NCT03313206

Jul 22nd, 2021 - The main objective will be to estimate the disease free survival (DFS) of patients with resectable head and neck mucosal melanomas treated by neo-adjuvant anti-PD1 followed by surgery, radiotherapy and maintenance immunotherapy in order to compare...

see more →

News  31 results

FDA Grants Orphan Drug Designation to Toripalimab for Small Cell Lung Cancer
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-toripalimab-for-small-cell-lung-cancer

Apr 21st, 2022 - The FDA has granted an orphan drug designation to the PD-1 inhibitor toripalimab as a potential therapeutic option for patients with small cell lung cancer (SCLC), according to an announcement from Coherus BioSciences, Inc. and Shanghai Junshi Bio...

New, Updated Data Demonstrate Promising Future in Advanced Melanoma
https://www.onclive.com/view/new-updated-data-demonstrate-promising-future-in-advanced-melanoma

Jan 14th, 2022 - Long-term and recent data readouts have fueled immunotherapeutic advances in the treatment of advanced melanoma. At the 6th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, Jeffrey S. Weber, MD, ...

Tebentafusp Represents a Potential Frontline Therapy for Patients with Uveal Melanoma
https://www.onclive.com/view/tebentafusp-represents-a-potential-frontline-therapy-for-patients-with-uveal-melanoma

Dec 2nd, 2021 - In findings from a recent phase 3 clinical trial (NCT03070392), the novel bispecific fusion protein tebentafusp (IMCgp100) showed statistically significant improvements in overall survival for patients with uveal melanoma, according to Richard D. ...

Nemvaleukin Alfa Plus Pembrolizumab Gets Fast Track Status for Platinum-Resistant Ovarian Cancer
https://www.onclive.com/view/nemvaleukin-alfa-plus-pembrolizumab-gets-fast-track-status-for-platinum-resistant-ovarian-cancer

Oct 26th, 2021 - The FDA has granted a fast track designation to the interleukin-2 (IL-2) variant immunotherapy nemvaleukin alfa (nemvaleukin) in combination with pembrolizumab (Keytruda) for the treatment of patients with platinum-resistant ovarian cancer.1 The ...

PVSRIPO Shows Promising Antitumor Activity in Refractory Melanoma
https://www.onclive.com/view/pvsripo-shows-promising-antitumor-activity-in-refractory-melanoma

Oct 6th, 2021 - Treatment with the novel intratumoral immuotherapy agent PVSRIPO resulted in an overall response rate (ORR) of 33% among all patients with anti–PD-1 refractory melanoma. Further, data from a phase 1 study demonstrated a 67% response among those wh...

see more →